0001145549-21-003922.txt : 20210128 0001145549-21-003922.hdr.sgml : 20210128 20210128113859 ACCESSION NUMBER: 0001145549-21-003922 CONFORMED SUBMISSION TYPE: NPORT-P PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201130 FILED AS OF DATE: 20210128 PERIOD START: 20210831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RBB FUND, INC. CENTRAL INDEX KEY: 0000831114 IRS NUMBER: 510312196 STATE OF INCORPORATION: MD FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: NPORT-P SEC ACT: 1940 Act SEC FILE NUMBER: 811-05518 FILM NUMBER: 21563190 BUSINESS ADDRESS: STREET 1: 615 E. MICHIGAN ST. CITY: MILWAUKEE STATE: WI ZIP: 53202 BUSINESS PHONE: 609-731-6256 MAIL ADDRESS: STREET 1: 615 E. MICHIGAN ST. CITY: MILWAUKEE STATE: WI ZIP: 53202 FORMER COMPANY: FORMER CONFORMED NAME: RBB FUND INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUND INC /DE/ DATE OF NAME CHANGE: 19600201 0000831114 S000063392 MFAM Small-Cap Growth ETF C000205459 MFAM Small-Cap Growth ETF MFMS NPORT-P 1 primary_doc.xml NPORT-P false 0000831114 XXXXXXXX S000063392 C000205459 RBB Fund, Inc. 811-05518 0000831114 5493005KKD0GVHSW0D29 615 East Michigan Street Milwaukee 53202 414-765-5366 MFAM Small-Cap Growth ETF S000063392 5493004DNMPH673GZ455 2021-08-31 2020-11-30 N 171828993.420000000000 36435906.480000000000 135393086.940000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 0.000000000000 N ADMA Biologics Inc N/A ADMA Biologics Inc 000899104 766362.000000000000 NS USD 1563378.480000000000 1.1546959415 Long EC CORP US N 1 N N Alarm.com Holdings Inc 549300HIH92U1EKIHZ32 Alarm.com Holdings Inc 011642105 56564.000000000000 NS USD 4293773.240000000000 3.1713386090 Long EC CORP US N 1 N N N Antares Pharma Inc 5299004QMIHMZUUNYY44 Antares Pharma Inc 036642106 935744.000000000000 NS USD 2919521.280000000000 2.1563296517 Long EC CORP US N 1 N N N Axon Enterprise Inc 549300QP2IEEGFE16681 Axon Enterprise Inc 05464C101 39834.000000000000 NS USD 5006735.460000000000 3.6979254799 Long EC CORP US N 1 N N Cardlytics Inc 549300JETJBH94EIPC66 Cardlytics Inc 14161W105 72406.000000000000 NS USD 8593144.080000000000 6.3468115501 Long EC CORP US N 1 N N Editas Medicine Inc 5299000AON4Q9NT2JE42 Editas Medicine Inc 28106W103 42053.000000000000 NS USD 1286401.270000000000 0.9501233032 Long EC CORP US N 1 N N Everbridge Inc 549300WCY0UMR64ATW81 Everbridge Inc 29978A104 39236.000000000000 NS USD 4980617.840000000000 3.6786352631 Long EC CORP US N 1 N N Fox Factory Holding Corp 529900GE1HSV0617R721 Fox Factory Holding Corp 35138V102 33497.000000000000 NS USD 2923283.190000000000 2.1591081613 Long EC CORP US N 1 N N N Globus Medical Inc 5299003M2P4CIK0RF205 Globus Medical Inc 379577208 64043.000000000000 NS USD 3847703.440000000000 2.8418758498 Long EC CORP US N 1 N N N Goosehead Insurance Inc 549300WH5MBIWHJ9XY95 Goosehead Insurance Inc 38267D109 41578.000000000000 NS USD 5118667.580000000000 3.7805974409 Long EC CORP US N 1 N N N HealthEquity Inc 529900LRJU1RAFQHM467 HealthEquity Inc 42226A107 70712.000000000000 NS USD 5069343.280000000000 3.7441669989 Long EC CORP US N 1 N N Heska Corp 529900O1OR2EB7L0HY27 Heska Corp 42805E306 38138.000000000000 NS USD 4767250.000000000000 3.5210438788 Long EC CORP US N 1 N N Howard Hughes Corp/The 549300BVHY25JZC1KI49 Howard Hughes Corp/The 44267D107 27473.000000000000 NS USD 1998111.290000000000 1.4757853116 Long EC CORP US N 1 N N N iRhythm Technologies Inc 549300FJI72RJGDQS384 iRhythm Technologies Inc 450056106 22499.000000000000 NS USD 5501230.490000000000 4.0631546369 Long EC CORP US N 1 N N John Bean Technologies Corp 5493007CT6ATBZ2L6826 John Bean Technologies Corp 477839104 31664.000000000000 NS USD 3500771.840000000000 2.5856355883 Long EC CORP US N 1 N N N Jones Lang LaSalle Inc 6SYKCME112RT8TQUO411 Jones Lang LaSalle Inc 48020Q107 46737.000000000000 NS USD 6182837.730000000000 4.5665830285 Long EC CORP US N 1 N N Landstar System Inc 254900CUQXQRL09MEI52 Landstar System Inc 515098101 21025.000000000000 NS USD 2763105.500000000000 2.0408024977 Long EC CORP US N 1 N N N Newmark Group Inc N/A Newmark Group Inc 65158N102 343723.000000000000 NS USD 2412935.460000000000 1.7821703564 Long EC CORP US N 1 N N N nLight Inc N/A nLight Inc 65487K100 224898.000000000000 NS USD 6751437.960000000000 4.9865455560 Long EC CORP US N 1 N N N PTC Therapeutics Inc 549300UJLWOIWFDGB318 PTC Therapeutics Inc 69366J200 100063.000000000000 NS USD 6260941.910000000000 4.6242700063 Long EC CORP US N 1 N N N Paylocity Holding Corp 549300VH75FTB4DIEE07 Paylocity Holding Corp 70438V106 41923.000000000000 NS USD 8242061.800000000000 6.0875056373 Long EC CORP US N 1 N N N Penumbra Inc 549300RGE06P3ECANU72 Penumbra Inc 70975L107 21315.000000000000 NS USD 4729798.500000000000 3.4933825699 Long EC CORP US N 1 N N Proto Labs Inc 529900QHG5MGWT2WQQ09 Proto Labs Inc 743713109 26976.000000000000 NS USD 3727004.160000000000 2.7527285508 Long EC CORP US N 1 N N Q2 Holdings Inc 549300M9RKR9DZXWS696 Q2 Holdings Inc 74736L109 41470.000000000000 NS USD 4701453.900000000000 3.4724475276 Long EC CORP US N 1 N N N Schrodinger Inc/United States N/A Schrodinger Inc/United States 80810D103 19330.000000000000 NS USD 1344981.400000000000 0.9933900101 Long EC CORP US N 1 N N N Smartsheet Inc 549300N9WF42OK9VL589 Smartsheet Inc 83200N103 61674.000000000000 NS USD 3578942.220000000000 2.6433714607 Long EC CORP US N 1 N N N STAG Industrial Inc 549300QWYX2W6FASVQ07 STAG Industrial Inc 85254J102 77038.000000000000 NS USD 2294191.640000000000 1.6944673409 Long EC CORP US N 1 N N N Trex Co Inc N/A Trex Co Inc 89531P105 35700.000000000000 NS USD 2671074.000000000000 1.9728289386 Long EC CORP US N 1 N N U.S. Bank Money Market Deposit Account N/A U.S. Bank Money Market Deposit Account 8AMMF0A92 7689683.700000000000 NS USD 7689683.700000000000 5.6795246152 Long STIV RF US N 1 N N N Ultragenyx Pharmaceutical Inc 529900EV44GVDN1DCX77 Ultragenyx Pharmaceutical Inc 90400D108 48343.000000000000 NS USD 5730579.220000000000 4.2325493491 Long EC CORP US N 1 N N Watsco Inc 549300F1Y3LN5BX5WN75 Watsco Inc 942622200 22040.000000000000 NS USD 5011014.400000000000 3.7010858628 Long EC CORP US N 1 N N N Mount Vernon Liquid Assets Portfolio, LLC N/A Mount Vernon Liquid Assets Portfolio, LLC N/A 36347138.500000000000 NS USD 36347138.500000000000 26.8456383716 Long STIV PF US N N/A N N 2021-01-28 RBB Fund, Inc. /s/ James G. Shaw RBB Fund, Inc. Treasurer XXXX NPORT-EX 2 small-cap_etf.htm NPORT-EX


MFAM SMALL-CAP GROWTH ETF
 
         
SCHEDULE OF INVESTMENTS
 
NOVEMBER 30, 2020 (UNAUDITED)
 
         
   
NUMBER OF
       
   
SHARES
   
VALUE
 
Common Stocks — 94.4%
           
Aerospace & Defense — 3.7%
           
Axon Enterprise, Inc. (United States)*(a)
   
40,108
   
$
5,041,174
 
Auto Components — 2.2%
               
Fox Factory Holding Corp. (United States)*
   
33,728
     
2,943,443
 
Biotechnology — 11.0%
               
ADMA Biologics, Inc. (United States)*(a)
   
771,647
     
1,574,160
 
Editas Medicine, Inc. (United States)*(a)
   
42,343
     
1,295,272
 
PTC Therapeutics, Inc. (United States)*
   
100,753
     
6,304,115
 
Ultragenyx Pharmaceutical, Inc. (United States)*(a)
   
48,676
     
5,770,053
 
             
14,943,600
 
Building Products — 2.0%
               
Trex Co., Inc. (United States)*(a)
   
35,946
     
2,689,480
 
Electronic Equipment, Instruments & Components — 5.0%
               
NLight, Inc. (United States)*
   
226,449
     
6,797,999
 
Equity Real Estate Investment Trusts (REITs) — 1.7%
               
STAG Industrial, Inc. (United States)
   
77,569
     
2,310,005
 
Health Care Equipment & Supplies — 16.1%
               
Antares Pharma, Inc. (United States)*
   
942,197
     
2,939,655
 
Globus Medical, Inc., Class A (United States)*
   
64,484
     
3,874,199
 
Heska Corp. (United States)*(a)
   
38,401
     
4,800,125
 
iRhythm Technologies, Inc. (United States)*(a)
   
22,654
     
5,539,129
 
Penumbra, Inc. (United States)*(a)
   
21,462
     
4,762,418
 
             
21,915,526
 
Health Care Providers & Services — 3.7%
               
HealthEquity, Inc. (United States)*(a)
   
71,199
     
5,104,256
 
Health Care Technology — 1.0%
               
Schrodinger, Inc. (United States)*
   
19,463
     
1,354,236
 
Insurance — 3.8%
               
Goosehead Insurance, Inc., Class A (United States)
   
41,864
     
5,153,877
 
Machinery — 5.3%
               
John Bean Technologies Corp. (United States)
   
31,882
     
3,524,874
 
Proto Labs, Inc. (United States)*(a)
   
27,162
     
3,752,702
 
             
7,277,576
 
Media — 6.3%
               
Cardlytics, Inc. (United States)*(a)
   
72,905
     
8,652,365
 
Real Estate Management & Development — 7.8%
               
Howard Hughes Corp., (The) (United States)*
   
27,662
     
2,011,857
 
Jones Lang LaSalle, Inc. (United States)(a)
   
47,059
     
6,225,435
 
Newmark Group, Inc., Class A (United States)
   
346,093
     
2,429,573
 
             
10,666,865
 
Road & Rail — 2.0%
               
Landstar System, Inc. (United States)
   
21,170
     
2,782,161
 
Software — 19.1%
               
Alarm.com Holdings, Inc. (United States)*
   
56,954
     
4,323,378
 
Everbridge, Inc. (United States)*(a)
   
39,506
     
5,014,892
 
Paylocity Holding Corp. (United States)*
   
42,212
     
8,298,879
 
Q2 Holdings, Inc. (United States)*
   
41,756
     
4,733,878
 
Smartsheet, Inc., Class A (United States)*
   
62,099
     
3,603,605
 
             
25,974,632
 
Trading Companies & Distributors — 3.7%
               
Watsco, Inc. (United States)
   
22,192
     
5,045,573
 
Total Common Stocks (Cost $89,214,171)
           
128,652,768
 
                 
Investments Purchased with Proceeds from Securities Lending Collateral — 26.7%
               
Mount Vernon Liquid Assets Portfolio, LLC, 0.15%
   
36,347,139
     
36,347,139
 
Total Investments Purchased with Proceeds from Securities Lending Collateral (Cost $36,347,139)
           
36,347,139
 
                 
Short-Term Investments — 5.6%
               
U.S. Bank Money Market Deposit Account, 0.03% (United States)(b)
   
7,689,684
     
7,689,684
 
Total Short-Term Investments (Cost $7,689,684)
           
7,689,684
 
                 
Total Investments (Cost $133,250,994) — 126.7%
           
172,689,591
 
Liabilities in Excess of Other Assets — (26.7)%
           
(36,362,329
)
NET ASSETS — 100.0%
               
(Applicable to 3,650,000 shares outstanding)
         
$
136,327,262
 
   

*
Non-income producing security.
     
(a)
All or a portion of the security is on loan. At November 30, 2020, the market value of securities on loan was $35,444,793.
(b)
The rate shown is as of November 30, 2020.
     


 
MFAM SMALL-CAP GROWTH ETF
NOTES TO THE SCHEDULE OF INVESTMENTS
NOVEMBER 30, 2020
(UNAUDITED)
                     
PORTFOLIO VALUATION — The Fund’s net asset value (“NAV”) is calculated once daily at the close of regular trading hours on the New York Stock Exchange (“NYSE”) (generally 4:00 p.m. Eastern time) on each day the NYSE is open. Securities held by the Fund are valued using the closing price or the last sale price on a national securities exchange or the National Association of Securities Dealers Automatic Quotation System (“NASDAQ”) market system where they are primarily traded. Equity securities traded in the over-the-counter (“OTC”) market are valued at their closing prices. If there were no transactions on that day, securities traded principally on an exchange or on NASDAQ will be valued at the mean of the last bid and ask prices prior to the market close. Fixed income securities are valued using an independent pricing service, which considers such factors as security prices, yields, maturities and ratings, and are deemed representative of market values at the close of the market. Foreign securities are valued based on prices from the primary market in which they are traded, and are translated from the local currency into U.S. dollars using current exchange rates. If market quotations are unavailable or deemed unreliable, securities will be valued in accordance with procedures adopted by the Company’s Board of Directors (the “Board”). Relying on prices supplied by pricing services or dealers or using fair valuation may result in values that are higher or lower than the values used by other investment companies and investors to price the same investments. Such procedures use fundamental valuation methods, which may include, but are not limited to, an analysis of the effect of any restrictions on the resale of the security, industry analysis and trends, significant changes in the issuer’s financial position, and any other event which could have a significant impact on the value of the security. Determination of fair value involves subjective judgment as the actual market value of a particular security can be established only by negotiations between the parties in a sales transaction, and the difference between the recorded fair value and the value that would be received in a sale could be significant.
                     
FAIR VALUE  MEASUREMENTS – The inputs and valuation techniques used to measure the fair value of the Fund's investments are summarized into three levels as described in the hierarchy below:
                     
•  Level 1 — Prices are determined using quoted prices in active markets for identical securities.
                     
•  Level 2 — Prices are determined using other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
                     
• Level 3 — Prices are determined using significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).
                     
The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
                     
The following is a summary of the inputs used, as of November 30, 2020, in valuing the Fund's investments carried at fair value:

   
TOTAL
   
LEVEL 1
   
LEVEL 2
   
LEVEL 3
   
INVESTMENTS MEASURED AT NET ASSET VALUE^
 
SMALL-CAP GROWTH FUND
                             
Common Stocks
 
$
128,652,768
   
$
128,652,768
   
$
-
   
$
-
   
$
-
 
Investments Purchased with Proceeds From Securities Lending Collateral
   
36,347,139
     
-
     
-
     
-
     
36,347,139
 
Short-Term Investments
   
7,689,684
     
7,689,684
     
-
     
-
     
-
 
Total Investments*
 
$
172,689,591
   
$
136,342,452
   
$
-
   
$
-
   
$
36,347,139
 

* Please refer to Schedule of Investments for further details.
^ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in the table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Schedule of Investments.
                     
At the end of each quarter, management evaluates the classification of Levels 1, 2 and 3 assets and liabilities. Various factors are considered, such as changes in liquidity from the prior reporting period; whether or not a broker is willing to execute at the quoted price; the depth and consistency of prices from third party pricing services; and the existence of contemporaneous, observable trades in the market. Additionally, management evaluates the classification of Levels 1, 2 and 3 assets and liabilities on a quarterly basis for changes in listings or delistings on national exchanges.
                     
Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Fund's investments may fluctuate from period to period. Additionally, the fair value of investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values the Fund may ultimately realize. Further, such investments may be subject to legal and other restrictions on resale or otherwise less liquid than publicly traded securities.
                     
For fair valuations using significant unobservable inputs, U.S. generally accepted accounting principles (“U.S. GAAP”) requires the Fund to present a reconciliation of the beginning to ending balances for reported market values that presents changes attributable to total realized and unrealized gains or losses, purchase and sales, and transfers in and out of Level 3 during the period. Transfers in and out between levels are based on values at the end of the period.  A reconciliation of Level 3 investments is presented only if the Fund had an amount of Level 3 investments at the end of the reporting period that was meaningful in relation to its net assets. The amounts and reasons for Level 3 transfers in and out of each level is disclosed when the Fund had an amount of total Level 3 transfers during the reporting period that was meaningful in relation to its net assets as of the end of the reporting period.
                     
For the period ended November 30, 2020, the Fund had no Level 3 transfers.
                     
For more information with regard to significant accounting policies, see the most recent semi-annual or annual report filed with the Securities and Exchange Commission.